Takeda gout drug Uloric loses first-line approval after FDA confirms death risks

FDA has slapped a boxed warning on Takeda's gout drug Uloric due to an increased risk of death. (FDA)

Takeda's gout drug Uloric just got pushed out of the first-line treatment club, thanks to a red flag on safety.

After sifting postmarketing data, the FDA decided Uloric does carry an increased risk of death compared to the older gout drug allopurinol. The agency has slapped a boxed warning on Uloric's label and is limiting Uloric’s use to patients “who have failed or do not tolerate allopurinol.”

That means the Takeda medication will be forced into a smaller population of some 8.3 million adult gout patients in the U.S. And that could cut seriously into the growth Uloric's been posting for the Japanese drugmaker.

FierceBiotech Executive Breakfast

Getting Real: The Changing Tide on Real-World Evidence in Drug Development

Join FierceBiotech and a panel of industry experts for an executive breakfast at BIO. We will discuss the impacts of real-world evidence on drug development and address the important questions that companies are facing including where to find the right talent & technology and how to deploy it internally or with partners. Join us in Philadelphia on June 5th for this important discussion.

“We believe the label updates are appropriate to ensure physicians and patients have comprehensive and accurate information to make informed treatment decisions,” a Takeda spokeswoman told FiercePharma in an emailed statement.

Uloric was approved by the FDA in 2009 after two failed attempts in 2005 and 2006. The agency turned Uloric back then because of cardiovascular problems that cropped up in clinical trials. A follow-up trial Takeda ran for its third run at approval didn’t raise the same safety flag, so the FDA gave Uloric a green light, but included the CV safety data in the “Warning and Precaution” section of its label.

The FDA also required Takeda to run a large postmarketing safety study—and the data once again showed reason for worry.

RELATED: Takeda hits FDA snag on Ninlaro, but its growth still helps drive revenue hike

“The imbalance in cardiovascular deaths between the two treatments was unexpected and warrants further analyses,” William White of the University of Connecticut School of Medicine, the lead investigator of the postmarket study, said in a statement last March.

In the 6,190-patient trial, Uloric’s rates of CV-related death and death from all causes were notably higher than those for allopurinol. The findings prompted a petition from nonprofit consumer advocacy group Public Citizen calling on the agency to pull Uloric’s approval.

Uloric is one of the growing drugs in Takeda’s portfolio. In the nine months ended in December, it raked in 40.5 billion Japanese yen ($366 million), up 15.7% year over year, with almost all sales coming from the U.S. The boxed warning and restriction to second-line use could put the drug’s growth in jeopardy.

Editor's Note: The story has been updated with a statement from Takeda.

Suggested Articles

Celltrion Chairman Seo Jung-jin says the South Korean company will spend about $33 billion over a decade on its biologics and pharma businesses.

Purdue took a big hit when it settled with Oklahoma over claims it misleadingly advertised its powerful opioid, OxyContin. Now more states want in.

The new endorsement of Celgene's Revlimid from England's cost watchdog NICE may not help calm fears about BMS' $74 billion buyout.